Precision BioSciences, Inc. filings document regulatory disclosures for a clinical-stage gene editing company built around the ARCUS platform and in vivo therapeutic candidates. Recent Forms 8-K furnish operating results, financial-condition updates, business presentations, and Regulation FD materials covering PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, including IND-related and clinical-development disclosures.
The company’s proxy materials address board and stockholder meeting matters, executive compensation, equity plans, and governance proposals. Other filing categories cover material agreements, shareholder voting matters, capital-structure disclosures, inducement awards, and forward-looking risk language tied to clinical development, financing capacity, regulatory review, and public-company reporting.
Bleichroeder LP and related entities have reported a significant ownership position in Precision Biosciences, Inc. They are deemed to beneficially own 1,900,000 common shares, representing 8.21% of the company’s common stock believed to be outstanding as of 12/31/2025.
The shares are held for various advisory clients of Bleichroeder LP, which is a registered investment adviser. Clients have the right to receive dividends and sale proceeds from these securities. The filing states that the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Precision Biosciences.
Precision BioSciences received U.S. FDA clearance of an investigational new drug application for PBGENE-DMD, its first-in-class in vivo gene editing therapy for Duchenne muscular dystrophy. This “Study May Proceed” notification allows initiation of site activation for the Phase 1/2 FUNCTION-DMD clinical trial in ambulatory patients.
PBGENE-DMD uses a gene excision approach to permanently correct dystrophin gene mutations between exons 45 and 55, a region affecting about 60% of boys with Duchenne muscular dystrophy. The therapy is designed to restore near full-length dystrophin protein at about 80% of normal size, substantially larger than micro-dystrophin constructs approved or in development.
The company plans to activate the first U.S. clinical site in the first half of 2026 and expects initial data from multiple patients by year end 2026. PBGENE-DMD has Rare Pediatric Disease and Orphan Drug designations, and a virtual investor event is planned in March to discuss the program and trial.
Precision BioSciences, Inc. received a significant ownership disclosure from Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia. The reporting group beneficially owns 2,328,485 common shares of Precision BioSciences, equal to 9.99% of the class.
The stake consists of 1,917,995 common shares held directly and 410,490 common shares issuable upon exercise of warrants. These percentages are based on 22,897,665 common shares outstanding as of December 30, 2025, as referenced from a Form S-3. The warrants are subject to a 9.99% beneficial ownership blocker, so they cannot be exercised if doing so would push the group above that threshold.
Voting and dispositive power over all 2,328,485 shares are reported as shared among the reporting persons. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Precision BioSciences.
Aberdeen Group plc and abrdn Inc. have disclosed a significant ownership stake in Precision BioSciences Inc. (DTIL). The reporting entities beneficially own 2,138,603 shares of Precision BioSciences common stock, representing 8.88% of the outstanding shares of this class as of 12/31/2025. They report zero sole voting or dispositive power, and shared voting and shared dispositive power over all 2,138,603 shares.
The firms state that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Precision BioSciences, nor in connection with any transaction intended to have that effect. abrdn Inc. indicates that it beneficially owns these shares on behalf of underlying clients, with Aberdeen Group plc as the parent company and abrdn Holdings Limited as intermediate holding company.
Precision BioSciences President and CEO Michael Amoroso reported routine equity activity tied to vesting of restricted stock units (RSUs) and related tax withholding. On January 20, 2026, RSUs covering 8,888, 37,069, and 69,421 shares vested and were converted into an equal number of common shares.
On January 22, 2026, Amoroso sold 34,799 shares of common stock at a weighted average price of $4.17 per share, in multiple trades between $3.97 and $4.30. The filing states these sales were made under a pre-arranged Rule 10b5-1 plan and were solely to cover tax withholding and fees from the RSU vesting. After these transactions, he directly held 196,154 common shares, plus 37,069 and 69,421 unvested RSUs.
Precision BioSciences (DTIL) reported insider equity activity by its General Counsel and Secretary, Dario Scimeca. On January 20, 2026, several tranches of Restricted Stock Units (RSUs) vested, resulting in the issuance of 1,978, 8,425 and 14,908 shares of common stock at an exercise price of $0 per share. These RSUs were granted in 2023 and 2024 and vest in three substantially equal annual installments, subject to continued service.
On January 21, 2026, Scimeca sold 8,854 shares of Precision BioSciences common stock at $4.03 per share in a transaction coded as a sale. According to the disclosure, this was a Rule 10b5-1 sell-to-cover transaction, with shares sold only to satisfy tax withholding and related fees arising from the RSU vesting. After these transactions, Scimeca directly held 44,715 shares of common stock.
Precision BioSciences Chief Financial Officer John Alexander Kelly reported routine equity compensation activity. On January 20, 2026, previously granted Restricted Stock Units vested, resulting in the delivery of 3,888, 13,900, and 26,575 shares of common stock, each RSU converting into one share. On January 21, 2026, Kelly sold 15,213 shares of common stock at $4.03 per share under a pre-established Rule 10b5-1 trading plan. The sale was a sell-to-cover transaction, with shares sold only to cover tax withholding obligations and related fees tied to the RSU vesting. After these transactions, Kelly directly held 106,448 shares of Precision BioSciences common stock.
Precision BioSciences Chief Research Officer J. Jefferson Smith reported RSU vesting and a related tax sale. On January 20, 2026, RSUs covering 2,500, 10,447, and 16,219 shares vested, each RSU representing one share of common stock. On January 21, 2026, Smith sold 10,200 shares of common stock at $4.03 per share under a pre-arranged Rule 10b5‑1 plan as a sell‑to‑cover transaction for tax withholding tied to the RSU vesting.
Following these transactions, Smith directly owned 110,184 shares of Precision BioSciences common stock and held an additional 7,931 shares indirectly through a charitable remainder unitrust. RSU holdings after the transactions included 10,447 and 16,219 units that remain subject to their vesting schedules.
Precision BioSciences plans an insider stock sale under Rule 144. A holder intends to sell 34,799 shares of DTIL common stock through Fidelity Brokerage Services LLC on or around 01/22/2026, with an indicated aggregate market value of $145,202.30. The shares are listed on the NASDAQ.
The securities to be sold were acquired on 01/20/2026 through restricted stock vesting from the issuer as compensation. The filing also notes that Michael Amoroso sold 3,409 common shares on 11/03/2025 for gross proceeds of $22,121.00. The signer represents that they are not aware of undisclosed material adverse information about the company’s operations.
Precision BioSciences, Inc. is the subject of a Schedule 13G reporting that investment manager Empery Asset Management, LP and Ryan M. Lane beneficially own 2,297,781 shares of its common stock, equal to 9.99% of the outstanding class. This total includes 103,146 shares issuable upon exercise of warrants, calculated using 22,897,665 shares of common stock outstanding as of November 10, 2025.
The filing explains that the warrants are subject to a 9.99% “Blocker,” which prevents the reporting persons from exercising warrants to the extent such exercise would push their beneficial ownership above 9.99%. Empery acts as investment manager to the funds that hold the shares and warrants, and Lane is described as an individual with indirect control over the investment manager. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Precision BioSciences.